PhRMA Condemns Medicare B Rx Drug Payment Experiment

The Pharmaceutical Researchers and Manufacturers of America (PhRMA) wasted no time in condemning the Obama administration's plans to launch a new experiment testing whether alternative payment designs may lead to reducing Medicare Part B expenditures, while preserving and potentially even enhancing beneficiaries' quality of care.

More from Anticancer

More from Therapy Areas